FRT vs RPRX · rev $1.28B vs P/E 15, rev $1.30B
FRT (FRT) versus Royalty Pharma Plc (RPRX) — a side-by-side from cached financials, not a winner call.
FRT (FRT) common stock.
Royalty Pharma Plc (RPRX) is a biotechnology company listed on US.
Latest reported FRT revenue for 2025-12-31 was $1.28B. Net income was $411.1M. Revenue was up 6.4% from 2024-12-31 to 2025-12-31. FRT currently screens at market cap $0.
Latest reported RPRX revenue for 2026-06-30 was $1.30B. Net income was $312.6M. RPRX currently screens at market cap $20.45B and trailing P/E 14.8.
FRT currently screens at market cap $0. RPRX currently screens at market cap $20.45B and trailing P/E 14.8.
Not investment advice. Open the FRT and RPRX stock pages for the full models.
Not investment advice.